Polpharma S.A. - Strategic SWOT Analysis Review

  • ID: 2673439
  • SWOT Analysis
  • 30 pages
  • GlobalData
1 of 4
Polpharma S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Our summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Polpharma S.A. (Polpharma) undertakes the research, manufacture and marketing of generic drugs, prescription drugs and over the counter medications. It provides drugs in cardiology, gastroenterology and neurology areas. The company also manufactures over the counter (OTC) medications, dietary supplements, cosmetic products, medical devices and phyto-pharmaceuticals as well as active pharmaceutical ingredients (APIs). Polpharma has seven manufacturing plants in Russia, Poland and Kazakhstan and seven research and development centres. The company operates in Central and Eastern Europe, the Caucasus and Central Asia markets. Polpharma group includes Santo, Medana SA, Akrikhin Pharmaceuticals, Polfa Warszawa S.A. Polpharma is headquartered in Starogard Gdanski, Poland.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with Our detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Section 1 - About the Company

Polpharma S.A. - Key Facts

Polpharma S.A. - Key Employees

Polpharma S.A. - Major Products and Services

Polpharma S.A. - History

Polpharma S.A. - Company Statement

Polpharma S.A. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Polpharma S.A. - Business Description

Polpharma S.A. - Corporate Strategy

Polpharma S.A. - SWOT Analysis

SWOT Analysis - Overview

Polpharma S.A. - Strengths

Strength - Comprehensive Product and Services Portfolio

Strength - Market Leading Presence

Strength - Network of Operating Companies and Manufacturing plants

Polpharma S.A. - Weaknesses

Weakness - Patent Infringement Concerns

Polpharma S.A. - Opportunities

Opportunity - Strategic Initiative: Biosimilar Drugs Production

Opportunity - Pipeline Product Portfolio

Opportunity - Growing Aged Population

Polpharma S.A. - Threats

Threat - Competitive Market

Threat - Increased Pricing Control

Threat - Uncertain R&D Outcomes

Polpharma S.A. - Key Competitors

Section 3 – Company’s Lifesciences Financial Deals and Alliances

Polpharma S.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Polpharma S.A., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Polpharma S.A., Recent Deals Summary

Section 4 – Company’s Recent Developments

Sep 28, 2015: Polpharma Has a New CEO

Jun 05, 2015: EIB supports pharmaceutical research and development in Poland with EUR 45m loan to Polpharma

Feb 17, 2015: Polpharma has successfully passed the US FDA inspection

Section 5 – Appendix

Methodology

About us

Contact Us

Disclaimer

List of Tables

Polpharma S.A., Key Facts

Polpharma S.A., Key Employees

Polpharma S.A., Major Products and Services

Polpharma S.A., History

Polpharma S.A., Other Locations

Polpharma S.A., Subsidiaries

Polpharma S.A., Key Competitors

Polpharma S.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Polpharma S.A., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Polpharma S.A., Recent Deals Summary

List of Figures

Polpharma S.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Polpharma S.A., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll